In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access.
Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.
In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.
Subscribe with your favorite podcasting platform.
For more information about MArS Market Access and Pricing Strategy visit:
In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.
They are discussing latest forecasts and potential policy implications.
Prof. Wagschal also explains limitations of forecasts and dynamics of recent elections.
Another important part is in the potential (new) coalitions and their likely impact on the health care market.
Subscribe at your favourite podcasting platform and for more information about MArS Market Access and Pricing Strategy visit:
In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany.
Mathias is a core stakeholder within the regional payer system in Germany at one of the most innovative Statutory Health Insurance Physician Associations (KV Westphalia-Lippe). Mathias brings the payer view into the discussion of 10 years AMNOG. Success or failure?